Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract outlines the issue of hair loss caused by various factors, including stress and autoimmune disorders like alopecia areata, which results in spot baldness, but does not provide specific study results.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

This review discusses the potential association between vaccination and alopecia areata, highlighted in case reports, notably with the hepatitis B virus vaccine, but provides no new results.

Vitiligo is caused by the immune system attacking skin pigment cells.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

This article proposes that alopecia areata may be caused by immune attacks on hair follicles after an immune privilege collapse, suggesting new therapeutic approaches targeting this immune response pattern.

This study reviews the role of hair follicles in the development, symptoms, and treatment options for vitiligo and alopecia areata, aiming to enhance understanding of their involvement in these autoimmune conditions and explore potential therapies.

Lichen Planopilaris causes irreversible hair loss due to immune attacks on hair stem cells, but modulating PPAR-γ might help treat it.

The excimer laser may help hair regrow in alopecia areata patients.

This review discusses various treatment options for alopecia areata, focusing on manipulating the immune response around hair follicles, but reports no new clinical results.

Scarring alopecia involves increased immune cells and specific gene changes near damaged hair follicles.

This review explores the complex factors involved in alopecia areata, such as immune and genetic influences, and discusses advances in diagnostic and therapeutic approaches, while reporting no new clinical results.

This review discusses the genetics, therapy, and prognosis of childhood alopecia areata, noting that while current treatments are not curative, new modalities may improve future outcomes; it reports no new clinical results.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

This review examines the interplay of genetics and neuroimmunology in alopecia areata, highlighting its potential to inform broader autoimmunity research, but reports no new findings.

This review provides a detailed overview of Hashimoto thyroiditis, discussing its epidemiology, risk factors, genetic and environmental contributors, clinical presentations, diagnostic methods, and treatment options, emphasizing the importance of personalized treatment plans due to varied causes and symptoms.

This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.

This study developed a technique to limit genetic recombination to regulatory T cells to investigate whether self-tolerance is maintained in non-lymphoid tissues, an area previously not well understood.

This study found that feeding mice high levels of dietary vitamin A increased WNT signaling, which activated hair follicle stem cells and may have accelerated alopecia areata progression.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

This review discusses the mechanisms underlying the collapse of hair follicle immune privilege in alopecia areata and emphasizes the importance of therapeutic strategies aimed at restoring immune tolerance.

This study observed that expanding regulatory T cells in the skin of mice with alopecia areata did not reverse the condition, indicating that additional immunotherapy may be necessary.

This study found that acute stress can cause rapid hair loss by triggering necrosis in hair follicle cells and initiating autoimmunity, revealing a mechanism where stress-induced nerve activity leads to tissue damage and immune system activation.

This review discusses various noninflammatory alopecias in horses, particularly alopecia areata, and reports no new treatment results, emphasizing the need for differential diagnosis through examination and biopsy.

This case report describes a post-COVID syndrome patient who experienced symptoms like headache, joint pain, and swollen lymph nodes; treatment with Erbisol drugs reportedly alleviated symptoms and normalized immunological parameters.

This review discusses autoimmune skin disorders, including lupus erythematosus and scleroderma, and their common treatments, reporting no new clinical results.

This review examines current research on antioxidants in autoimmune skin diseases like alopecia areata and vitiligo, concluding with suggestions for future studies and treatment possibilities without reporting new clinical results.

This case report describes a 26-year-old man from Bangladesh diagnosed with autoimmune polyendocrine syndrome type 1, a rare endocrine disorder involving adrenocortical insufficiency, hypoparathyroidism, and mucocutaneous candidiasis.

This mini-review discusses the role of androgens, specifically testosterone and dihydrotestosterone, in the pathogenesis of autoimmune liver diseases and reports no new results.

This review discusses the role of gut microbiota in autoimmune and immune-mediated dermatological conditions like lupus and psoriasis, but reports no new clinical results; the authors emphasize the need for further study into microbial signatures and treatments.